Conference Highlights

Infectious Diseases and Global Health

Basic definition of infection refers to the harm caused by a foreign particle entering the host body. Some are mild and few are life-threatening depending on the type of organism causing it. Starting from the cause, symptoms, detecting the organism, clinical studies, treatment, controlling it before spreading, preventing the infection, developing new methods and techniques for diagnosis to developing new drugs and treatment strategies, you can discuss at our Euro Infectious Diseases 2020

The global market for infectious disease treatments is a result of the growth in demand for new pharmaceutical treatments, vaccines development, and environmental products. In 2017, the global market for the treatment of infectious disease totaled $64.8 billion. The market should total $99 billion by 2022, growing at a CAGR of 8.9% from 2017 to 2022.

Sub-Tracks

Causes and pathophysiology
Classification (Viral, Bacterial, Fungal and prion infections)
Diagnosis and Prevention
Prevalence and Epidemiology
Clinical Studies
Pharmaceutical Research
Tropical Diseases

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Viral Infections

These viral infections usually last for 7-10 days on which even medications won’t be much effective for the treatment. Resting and intake of fluids mostly work. But few cases like HIV, Ebola and Hepatitis are chronic and need to be treated with medications. Different viruses attack liver, respiratory system, or blood even. Immune system plays a critical role here and vaccination comes helpful in some cases.

Global virology market is estimated to witness significant growth over the forecast period. The global viral infections market will grow from $74 billion in 2014 to $117.6 billion by 2021, representing a CAGR of 6.8%

Sub-Tracks

Coronavirus Infections
Hepatitis
Influenza and Respiratory Infections
Encephalitis and Meningitis
Gastrointestinal Infections
Skin Infections
Placenta and fetus infection
Anti-viral drugs

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Bacterial Infections

Unlike Viral infections, bacterial infections can be treated with medications, antibiotics. Many species are even beneficial to our body but few cause infections which can be effectively treated using antibiotics. Immunization prevent the onset of many bacterial infections. This session discusses the complete details of these infection and also the research being carried out to fight the bacteria which are becoming antibiotic resistant

The global antibacterial drugs market was valued at $46.37Bn in 2018 and is estimated to increase at a CAGR of 1.5% from 2019 to 2027. North America stands first in the global antibacterial drugs market (2018). Global bacterial vaginosis drugs market research analysts estimate that it will generate revenue of almost USD 1 billion by 2021.

Sub-Tracks

Tuberculosis
Pneumonia
Cholera and Diphtheria
Bacterial Meningitis
Tetanus
Lyme disease
Gonorrhea and Syphilis
Skin and Urinary Tract Infections
Sepsis & Septicemia

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Fungal Infections

Fungal infection can be both superficial and can also penetrate deep inside the body. They trigger the immune system causing inflammation or tissue damage. Both the topical treatment and drugs are used to treat these infections. This session deals with all those aspects related to fungal infections

The global antifungal drugs market size was valued at USD 11.3 billion in 2017. Raising prevalence of fungal infections such as Aspergillosis and Candidiasis is the key factor propelling the market. Global Antifungal Drugs Market is predicted to rise from 13,719 USD million in 2016 to 17,718 USD million by 2023. The industry is anticipated to register a CAGR of 3.7%, during the forecast period of 2017 - 2023.

Sub-Tracks

Aspergillosis and Candidiasis
Athlete’s foot
Ringworm and Yeast infections
Skin Fungal Infections
Fungal Diseases in Soil
Anti-Fungal therapies

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Vector-borne Diseases

These are the infections transmitted by the mosquitoes, bugs, ticks, flies etc. One major factor that influences their growth is climate. These accounts for more than 17 percent of all infectious diseases. Dengue and Malaria are the major ones causing more number of deaths. Maintaining clean and proper environmental factors and social factors will helps in disease control and elimination

Global Anti-Malarial Drugs market reached USD 742.5 Million in 2016 at a CAGR of 3.2% across the world. The market is predicted as USD 1,049.5 Million by 2027. Middle East & Africa accounts for a share of 51.0% by 2027 and Asia Pacific of 30.2% by 2027. Moreover, the market is anticipated to account $317.0 Million by 2027 from $222.8 Million in 2016. China & India is the major contributor to the growth of Asia Pacific Anti-Malarial Drugs market.

Sub-Tracks

Malaria
Dengue fever and Chikungunya
Leishmaniasis and Yellow fever
Zika and Lymphatic filariasis
Schistosomiasis
Japanese encephalitis and Onchocerciasis

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Virology and HIVAIDS

With the continuous emerging of new strains of viruses, virologists played a major role in finding new advancements to fight against them. They became the most complex organisms causing dreadful diseases. One among them is the HIV-1, a retrovirus causing AIDS making the immune system the primary target. It has been around 20 years, our scientists researching on this HIV and though antiretroviral drugs reduced the mortality rate, still lot more research to be done to eradicate this completely. Join us and share your thoughts alos on this hot topic

In 2019, the global antiviral drugs market size was valued at $56.4 billion and is expected to register a CAGR of 2.3% over the estimated period. Around 1,848 pipeline products are specifically in development for treating the viral infections. Global HIV Drug Market was valued at USD20,448 million in 2015 and is predicted to reach USD26,458 million by 2022, at a CAGR of 3.7% during the forecast period of 2016-2022.

Sub-Tracks

Molecular virology of HIV & Viral Therapy
Viral genomes
Viral Pathogenesis and Immunity
Viral Evolution and Emerging Viruses
HIV/AIDS Epidemiological Statistics
Anti-HIV Drugs
Animal Models of HIV Infection and Disease

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Immunology and Clinical Microbiology

To understand the infectious diseases, we need to study deeply both the immunology and microbiology as one focuses on host and the other on pathogen affecting the host. Here we planned this particular session to discuss in detail to have better understanding of Infectious diseases including genetics, biochemistry, molecular and computational biology, molecular and cellular components of the immune system

Global immunology treatment market is set to expand, from $61.5 billion in 2015 to reach $74.2 billion in 2022. The pharmaceutical pipeline for immunology is countable, currently with 1,896 products in active development. 85 of these are in Phase III and 73% of these pipeline products are in the early developmental stages. The global immunology market size was USD 77,365.4 Million in 2018 and is estimated to reach USD 143,833.2 Million by 2026

Sub-Tracks

Immunology and Hypersensitivity
Host-Microbe Interactions and Pathogenesis
Molecular and Cellular Mechanisms
Molecular Genetics
Autoimmune and Inflammatory Diseases

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Neurological and CNS Infections

Bacteria, Virus and Fungi can even affect the Central Nervous System of our body. They may affect brain, spinal cord, neurons at any level. Initial prognosis and diagnosis is essentially required to save the life. Share your research work and help many individuals facing adverse consequences because of these infections

The global Central Nervous System therapeutic market size was worth $77.2 billion in 2016 and is expected to grow at a CAGR of 5.9% during the forecast period. The annual incidence of bacterial CNS infections has been 36.3/100,000 and that of viral infections is 688.0/100 000.

Sub-Tracks

Encephalitis
Prion diseases
Meningitis
Brain abscesses

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Healthcare-Associated Infections

HAIs are the infections that people usually get when they are getting treated for some other disease/disorder. These are having devastating consequences and may be the significant cause of illness and death. Hospitals, surgical centers, clinics are the major places for these kind of infections. 1 among every 25 hospitalized patients acquire HAIs so there comes the need of discussions on these Healthcare associated Infections

Sub-Tracks

Central line-associated bloodstream infection (CLABSI)
Methicillin-resistant Staphylococcus aureus (MRSA)
Catheter-associated urinary tract infections
Surgical site infections
Bloodstream infections
Clostridium difficile infections

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Ophthalmological Infectious Diseases

As mentioned earlier above, emerging infectious diseases became life threatening because of globalization. Now these find their way even in Ophthalmology causing infections to eye. This session describes the infections of eye in detail and how they can be diagnosed and treated with the recent advancements of the research field

Sub-Tracks

Retinitis and Chorioretinitis
Retinal Vasculitis
Optic Neuropathy
Ocular Immunology
Trachoma and Conjuctivitis

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Lower Respiratory and Pediatric IDs

Neonatal Diseases are very common as they will be consistently subjected to the infections caused by microbes. They can be of any reason/unknown reason or acquired from mother. Special attention should be given while treating them with the medications/vaccines or course of medications as their body molecular structure will be different and sensitive from that of adults especially while treating life threatening diseases. Learn more from the physicians and specialists expertise in the pediatric care

Sub-Tracks

Immune deficiency diseases
Encephalitis
Lymphadenopathy
HIV and Lyme disease
Osteomyelitis
Pneumonia and Tuberculosis

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Genomics and Infectious disease

This became the most interesting field now a days with the evolving nature of microbes. To know the information of an infection and its epidemiology etc the genomic study of the microbial strains is the only way to study about the disease further. Thus it plays a major role in prognosis, drug development, diagnosis and its epidemic control etc

Genome sequencing
Genomic advances
Research Studies and reports
Clinical and Epidemiologic studies
Current Clinical Applications

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Special Session on COVID-19

Coronaviruses cause illness to humans ranging from the common cold to dreadful diseases. COVID-19 is a new strain discovered in the year 2019 which has not identified previously in humans. They are transmitted from animals to humans. Common signs include respiratory discomfort, fever and cough, shortness of breath and breathing difficulties. To prevent the spreading of the infection regular hand washing, covering mouth and nose while coughing and sneezing, thoroughly cooking meat and eggs is highly recommended. It is better to avoid close contact with the one showing symptoms of respiratory illness such as coughing and sneezing.

This session was designed to discuss the recent research going on which will aid in giving new ideas and new ways to combat this dreadful disease spreading all across the globe

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Vaccines and Immunizations

Unlike other drugs used to treat the diseases, vaccines completely prevent the disease and thus became the effective way of treatment for many dangerous life threatening diseases. Immunization or Vaccination is generally done in childhood age to protect against the infection. Various forms of vaccinations were discovered. There by discussions will be on different types of vaccines for infections, their research and development stages etc..

Global vaccines market is estimated to reach $58.4 billion by 2024 from $41.7 billion in 2019, at a CAGR of 7.0% during the forecast period. This is driven by the rise in prevalence of infectious diseases and vaccines are considered the best way to prevent these infectious diseases.

Sub-Tracks

Vaccine Research & Development
Vaccines safety & Efficacy
Live-attenuated and Inactivated vaccines
Conjugate and Toxoid vaccines
Immunization for Women

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Tropical Diseases and Parasitic Diseases

Some bacterial and viral infections are restricted to specific tropical/sub-tropical regions causing Tropical diseases. This may be due to environmental/biological factors. Neglected tropical diseases (NTDs) are also the cases reported in these regions of low and middle income countries who don’t have proper sanitation in their living areas. Effective control need to be achieved by educating everyone with proper health approaches.

Parasites are the small organisms causing various types of infections in the host body. Even though all these are interlinked there is need to specifically address these parasitic diseases as many contagious diseases were reported from these.

The global neglected tropical disease treatment market size was accounted for $1.2 billion in 2018 and is estimated to grow at a CAGR of 5.5% over the forecast period. The global parasitic diseases therapeutics market size might grow by $1.79 billion during 2019 to 2023.

Sub-Tracks

Neurocysticercosis
Giardia and Helminthiasis
Leishmaniasis
Schistosomiasis and Trichinosis
Human African Trypanosomiasis

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Sexually Transmitted Diseases and STIs

STDs and STIs are having a profound impact on sexual and reproductive health globally. Every year, there are an estimated 376 million new infections. Gonorrhoea, Chlamydia, Syphilis and Trichomoniasis are most commonly seen. HSV and HPV are the viruses causing these infections. These are causing the major death in women and newborns which need to be focused on.

In 2017, global STD testing market was valued for $ 86,548.0 million. It is predicted to reach USD 133,935.7 million by 2025, at a CAGR of 5.6% from 2018- 2025. The diagnosis of these STDs caused by Syphilis is rising and is expected to account for over 20% of the market by 2022, growing at a CAGR over the forecast period due to high prevalence of syphilis infections globally.

Sub-Tracks

Chlamydia
Genital herpes
Trichomoniasis
Syphilis and Gonorrhea
Other STDs

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Pathophysiology and Diagnosis

Knowing about these Infectious Diseases is much more important to proceed for the treatment. Here comes the necessity of studying pathophysiology of the diseases and also the correct and accurate method for diagnosing it. Many advancements took place in the field of diagnostic studies. Let’s discuss about all the research advancements and pathophysiological studies

Sub-Tracks

Pathogenesis
Modes of Transmission
Antimicrobials/Antimicrobial Resistance
Molecular Methods
Infectious Agents and defense mechanisms
Novel methods and techniques

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Clinical Trials and Case Studies

Clinical Trails are very important before releasing a novel medicine to the market. It might take few years to complete. Not only for treatment methods but also for diagnosing or detecting new possible ways to treat diseases. Case studies play equal importance in exploratory research. These provide the clinical evidence documentation which can be helpful for the fellow researchers to study as well

Sub-Tracks

Evaluation of Safety and Efficacy of novel drugs
Research studies on IDs
Reviews on IDs
Drug Developmental Stages
Animal and Mathematical Models

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Influencing Factors of IDs

Now comes the session explaining the factors that influences the onset and spreading of Infectious Diseases. These may vary from environmental to biological. A brief idea about the factors helps for the further study regarding the diseases.

Sub-Tracks

Environmental factors
Biological and Social factors
Human and physical resources
Food and Water borne infections
Veterinary infectious Diseases

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Advanced Treatments and Technologies

With the overview we had about the IDs, our scientists have designed many medications and vaccines to prevent the diseases which had effectively showed the results. But due to emerging forms of infections still we have been struggling to fight against the infections. This session helps to discuss regarding the strategies or methods which are being developed.

Sub-Tracks

Novel Drug Therapies
Novel imaging and screening techniques
Technologies and devices
Biomarkers
Antibiotics, antiviral drugs and vaccines
Infection and Drug Resistance
Nursing Care Practices

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Prevention and Control

IDs still became a major concern occurring frequently across the world. There is definite necessity to follow few things to prevent or control these diseases. This session includes those preventive measures to be taken and follow for well-being of every individual. This includes maintaining hygienic environment within and around ourselves taking individual responsibility and following the guidelines issued by the authorities in regards to health and safety

Sub-Tracks

Vaccination
Genomic study
Antibiotics and Anti-microbials
Biochemical Tests
Drugs and risk factors

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Public Health and Epidemiology

Epidemiology of an infectious disease (ID) involves the study of prevalence and incidence of infections to better understand the burden and causes among the populations. These are one of the major cause of morbidity and mortality globally. The study ranges from the search of novel pathogens, Causative organism, Host, Mode of transmission, Incubation period, usual symptoms, complications and mortality rate using advanced molecular techniques to population based studies to explain the transmission dynamics & spectrum of disease.

Sub-Tracks

Endemic, Epidemic and Pandemic cases
Disease agent, host and the environment
Global Burden
Infectious Disease Spectrum studies
Public Health Surveillance studies
Data collection, Analysis, Interpretation and Dissemination

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Oral and Maxillofacial Infections

Odontogenic infections are mostly and frequently seen among the individuals. Due to the advancements in the medical field, techniques, antibiotic usage and genetics there is a need to discuss the advancements in this specific field

Epidemiological characteristics
Microbiological analysis
Treatment Techniques
Controversies

Tags

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Scope & Importance

Infectious Diseases and Antimicrobial Resistance Market Overview

The infectious diseases and antimicrobial resistance (AMR) market is growing as drug-resistant infections rise worldwide. The antibiotic resistance segment is valued at USD 9.3 billion in 2025 and projected to reach USD 12.1 billion by 2030 (CAGR 5.5%). Growth is fueled by increasing cases, public–private funding, and regulatory support. Asia-Pacific leads the market, South America shows the fastest growth, and pneumonia remains the largest disease segment.

The AMR diagnostics market, worth USD 4.6 billion in 2024, is expected to hit USD 6.7 billion by 2030 (CAGR 6.6%). Demand is rising for rapid, point-of-care tests, especially PCR-based technologies. North America currently dominates, but India and other emerging economies are expanding quickly, driven by the need for early detection and better antibiotic stewardship.

The AMR surveillance market is valued at USD 6.24 billion in 2025 and forecasted to reach USD 8.23 billion by 2030 (CAGR 5.7%). Growth is driven by molecular diagnostics, AI-powered analytics, and government programs. North America holds the largest share, while Asia-Pacific is the fastest-growing region. Hospitals remain the main users, with diagnostic labs gaining momentum.

Despite this momentum, the sector faces challenges: the low profitability of antibiotics, high development costs, and weak investment, especially in low- and middle-income countries. Still, opportunities lie in next-generation therapies such as bacteriophages, CRISPR-based drugs, and microbiome solutions, alongside AI-driven surveillance and portable diagnostics. With sustainable financing and global cooperation, these innovations could transform the AMR landscape and strengthen the fight against infectious diseases.

Infectious Diseases and Antimicrobial Resistance Market Overview in USA:

The U.S. infectious diseases market is one of the most advanced globally, valued at over USD 24 billion in 2025, with a projected CAGR of 6–7% through 2030. Growth is driven by increasing hospital-acquired infections (affecting nearly 1 in 31 patients daily, CDC) and viral threats such as influenza, RSV, and COVID-19 variants. The U.S. accounts for a significant share of global vaccine revenues, with the influenza vaccine market alone expected to exceed USD 6.5 billion by 2028. Advanced diagnostic platforms, particularly rapid molecular tests, are also expanding at a CAGR of nearly 9%, reflecting the demand for early detection and containment of outbreaks.

Antimicrobial resistance (AMR) remains a major challenge, causing 2.8 million infections and 35,000 deaths annually in the U.S. (CDC, 2023). The U.S. AMR therapeutics market is valued at USD 3.5–4 billion in 2025, and expected to grow at a CAGR of 5% due to rising resistance in pathogens such as E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Federal funding has increased, with initiatives like CARB-X awarding over USD 360 million to early-stage AMR projects and BARDA investing more than USD 1 billion in advanced-stage antibiotic and diagnostic development. Rapid diagnostic tests for AMR are also gaining traction, with adoption projected to grow 2x by 2030.

Looking ahead, the U.S. infectious diseases and AMR market is poised for steady expansion, projected to reach USD 33–35 billion by 2030. Government incentives such as the FDA’s QIDP designation, which provides market exclusivity and priority review for new antibiotics, are encouraging innovation. However, the market faces hurdles: the average cost of antibiotic R&D exceeds USD 1.5 billion, while uptake remains slow due to stewardship programs and reimbursement challenges. Despite these barriers, strong federal support and industry investment position the U.S. as a global leader in infectious disease management, with increasing focus on next-generation antibiotics, vaccines, and precision diagnostics to combat AMR.

Infectious Diseases and Antimicrobial Resistance Market Overview in Europe:

The commercial landscape in Europe is being reshaped by hard epidemiology and rising stewardship pressure. AMR is linked to 35,000+ deaths every year in the EU/EEA and an estimated 865,000+ resistant infections annually; the economic drag is ~€11.7 billion per year (PPP) across EU/EEA economies, a recurrent burden that continues to justify spend on novel antibiotics, rapid diagnostics, and infection-prevention solutions. On the demand side, antibiotic consumption fell sharply by 17% from 2018 to 2021, then rebounded to 19.8 DDD/1,000/day in 2023 (vs. 20.1 in 2018)—signalling renewed utilization post-pandemic and exposing variation across member states that vendors must factor into go-to-market plans. In 2023, about 90% of use sat in the community (18.3 DDD/1,000/day) versus 1.6 in hospitals, keeping primary care channels central for stewardship tech and point-of-care diagnostics.

Policy and funding are strong tailwinds. The 2023 EU Council Recommendation sets One-Health targets on IPC, stewardship and national action plan execution, while the Commission and ECDC ramp guidance and monitoring—creating compliance-driven demand for surveillance and IPC solutions. The EU’s health security arm HERA commands ~€2.8 billion (EU4Health) and ~€1.7 billion (Horizon Europe) for 2022–2027, and recent calls include a €13 million instrument for rapid point-of-care susceptibility testing—clear signals for diagnostics innovators. For 2025 specifically, the EU4Health work programme allocates €357.6 million to HERA actions, with procurement and grants as key vehicles—relevant for scale-up pathways and public tenders.

Market access is also moving: Europe has approved new agents (e.g., Emblaveo and Exblifep) for difficult Gram-negative infections, expanding the treatable addressable market while emphasizing antimicrobial stewardship frameworks at launch. Meanwhile, lawmakers debate transferable exclusivity vouchers (TEVs) as a pull incentive—industry sees them as catalytic, while public-health groups raise affordability and spillover concerns. Whichever design prevails, a predictable EU pull-incentive is the swing factor for late-stage pipeline investment and partnering decisions through 2030.

Infectious Diseases and Antimicrobial Resistance in Asia:

The infectious diseases and antimicrobial resistance (AMR) market in Asia is expanding rapidly, driven by rising infection rates, high antibiotic misuse, and increasing healthcare investments. The Asia-Pacific antibiotic resistance market was valued at USD 2.34 billion in 2023 and is projected to reach USD 3.57 billion by 2030, reflecting a CAGR of about 6.2%. In parallel, the AMR diagnostics segment is expected to grow from USD 1.05 billion in 2024 to USD 1.64 billion in 2030, at a 7.8% CAGR, while the antimicrobial susceptibility testing (AST) market is forecast to expand from USD 627.6 million in 2023 to USD 967.5 million by 2030 (CAGR 6.4%). These figures show that Asia is becoming a key growth hub for both therapeutic and diagnostic solutions in AMR, reflecting both the severity of the regional burden and growing demand for stewardship technologies.

The health burden of AMR in Asia is particularly severe. Globally, 5 million deaths in 2019 were linked to AMR, of which 1.27 million were directly attributable. South Asia recorded some of the world’s highest mortality, with 21.5 deaths per 100,000 population due to AMR, while Southeast and East Asia saw 11.7 per 100,000. In the WHO South-East Asia Region alone, sepsis accounted for 4 million deaths in 2019, and up to 1.41 million of these were linked to bacterial AMR. For India, the estimated toll was 297,000 deaths from resistance in a single year. Resistance trends are worsening: between 2016 and 2021, E. coli susceptibility to imipenem fell from 86% to 64%, while Klebsiella pneumoniae dropped from 65% to 43%. In 2021, carbapenem resistance in Acinetobacter baumannii reached 87.5%, and methicillin-resistant Staphylococcus aureus (MRSA) rose from 28.4% to 42.6% over the same period.

Behavioral and systemic factors continue to accelerate resistance across Asia. Self-medication rates for antibiotics range from 9% to 62% across the region, often linked to misconceptions about their effectiveness against viral infections like colds and flu. In Indonesia, around 75% of respondents believed antibiotics could treat viral illnesses, while in China, more than half of people reported antibiotic use within six months, with about 5% sourcing drugs online. Meanwhile, the agricultural sector is a major contributor: antibiotic use in animal husbandry across China and India is projected to double by 2030, creating spillover risks into human populations. The pace of urbanization is another driver, with Asia expected to host 27 of the world’s 43 megacities by 2030, where high population density and poor sanitation amplify transmission of resistant pathogens. Together, these drivers underscore both the urgency of policy and market interventions and the strong opportunity for solutions spanning novel antibiotics, rapid diagnostics, infection-control systems, and stewardship programs.

Infectious Diseases and Antimicrobial Resistance in Middle East:

The Middle East is emerging as a pivotal region in the global infectious diseases and antimicrobial resistance (AMR) landscape, shaped by rapid population growth, expanding healthcare infrastructure, and heightened vulnerability to outbreaks. The antibiotic resistance treatment market across the Middle East and Africa was valued at approximately USD 215 million in 2023 and is projected to grow to USD 316.9 million by 2030, advancing at a 5.7% CAGR. Alongside this, the AMR diagnostics market generated USD 213.5 million in 2024 and is expected to rise to USD 314.3 million by 2030, supported by a 6.7% CAGR. Countries such as Saudi Arabia and the UAE are outperforming the regional average, with diagnostics growth rates of 6.9% and 7.1% respectively, reflecting strategic government investment in laboratory networks, genomic surveillance, and digital health platforms.

In therapeutics, the market is showing steady but moderate expansion. The infectious disease therapeutics sector stood at USD 8.2 billion in 2024 and is projected to reach USD 9.61 billion by 2030, at a 3.7% CAGR. While large in value, this segment is less dynamic than diagnostics, underscoring limited antimicrobial innovation and a growing emphasis on early detection and stewardship over reliance on new drug launches. On the other hand, the infectious disease diagnostics market overall is growing at nearly triple the pace, forecasted to increase from USD 1.76 billion in 2024 to USD 3.96 billion by 2033, achieving a 9.4% CAGR. This surge is being fueled by persistent post-COVID testing culture, expanded molecular testing capacity, and new funding for health security programs across Gulf and North African nations.

Universities and Research Institutes:

USA

Europe

Asia/Middle East

University of Malaya / Sunway University / Monash University Malaysia / Cyberjaya University College of Medical Sciences / Universiti Tunku Abdul Rahman (UTAR) / La Trobe University / The University of Adelaide (UoA) / University of Wollongong / Curtin University / Flinders University / Victoria University / Swinburne University of Technology / University of Newcastle / Tunku Abdul Rahman University College / Raffles University / Sunway College Johor Bahru / ASIA Metropolitan University / KDU Penang University College / RCSI & UCD Malaysia Campus / Nilai University / Universiti Kuala Lumpur (UniKL) / Universiti Putra Malaysia (UPM) / Universiti Teknologi Malaysia (UTM) / Universiti Sains Malaysia (USM) / UCSI University / International Medical University (IMU) / Taylor's University / The University of Nottingham Malaysia Campus / The Hong Kong Polytechnic University / The University of Hong Kong / Hong Kong University of Science and Technology / City University of Hong Kong / Hong Kong Baptist University / The Education University of Hong Kong (EdUHK) / Lingnan University / Upper Iowa University / Hong Kong Shue Yan University / Hong Kong Adventist College / PSB Academy / National University of Singapore (NUS) / Nanyang Technological University (NTU) / James Cook University Singapore / Singapore Institute of Technology (SIT) / Kaplan Higher Education Academy / STEi Institute / Duke-NUS Medical School / NIE Singapore (NTU) / Parkway College of Nursing and Allied Health / HMI Institute of Health Sciences

Hospitals and Medical Centers

USA

Upper River Valley Hospital / Hackensack University Medical Center / Legacy Salmon Creek Medical Center / Houston Methodist Hospital / Hartford Hospital / University of Pittsburgh Medical Center / University of Texas MD Anderson Cancer Center / UCLA Health: Ronald Reagan UCLA Medical Center / Mercy San Juan Medical Center / Massachusetts General Hospital / Stanford Hospital & Clinics / Cleveland Clinic / Mayo Clinic Cancer Center / Palomar Medical Center / Johns Hopkins Hospital / El Camino Hospital / Abbott Northwestern Hospital / Banner – University Medical Center Phoenix / Ann & Robert H. Lurie Children's Hospital of Chicago / Aurora St. Luke's Medical Center / Baylor St. Luke's Medical Center / Beaumont Hospital / Boston Children's Hospital / Brigham and Women's Hospital / Carolinas Medical Center / Cedars-Sinai Medical Center / Children's Hospital Los Angeles / The Christ Hospital / Dartmouth-Hitchcock Medical Center / Duke University Hospital / Emory University Hospital / Florida Hospital Orlando / Geisinger Medical Center / Inova Fairfax Hospital / Intermountain Medical Center / Lehigh Valley Hospital–Cedar Crest / Loyola University Medical Center / National Institutes of Health Clinical Center / Nebraska Medicine – Nebraska Medical Center / Rush University Medical Center / Thomas Jefferson University Hospitals

Europe

Nuffield Health Bristol Hospital / Vale Hospital / Guy's and St. Thomas' / Asklepios Klinik Barmbek / Clinical Centre of Serbia / Charite – Universitatsmedizin Berlin / Helsinki University Central Hospital / Motol University Hospital / Sahlgrenska University Hospital / Vienna General Hospital / Semmelweis University Hospital / University Hospitals of Geneva / University Hospital Pilsen / LKH Klagenfurt / University Medical Center Freiburg / Armavir Medical Center / ArBeS Healthcare Center for Rehabilitation / Armenicum Clinical Center / Tsaghkahovit Medical Center / Vedi Medical Center / Tsaghkahovit Medical Center / Sf. Gheorghe Hospital / Pitești Pediatric Hospital / Pitești County Emergency Hospital / Bistrița Năsăud County Emergency Hospital / Arad County Emergency Clinical Hospital / Topolšica Hospital / Golnik University Clinic of Respiratory and Allergic Diseases / Novo Mesto General Hospital / Jesenice General Hospital / Ljubljana University Medical Centre / Bispebjerg Hospital / Rigshospitalet / Ringsted Sygehus / Frederiksberg Hospital / Fåborg Hospital / Nyborg Hospital / Svendborg Hospital / Regionshospitalet Holstebro / Aalborg Sygehus / Parkens Privathospital / Hospital of Jerez de la Frontera / Hospital Santa María del Puerto / Hospital Universitario Princesa de España / Hospital Virgen De La Victoria / Hospital Clínico Universitario Lozano Blesa / Hopital Central Universitario de Asturias / Hospital Universitario de Gran Canaria Doctor Negrín / Hospital Virgen de la Salud

Asia/Middle East

Wooridul Spine Hospital / Ramkhamhaeng Hospital / Wattanosoth Cancer Hospital / Gleneagles Medical Center / Clemenceau Medical Center / Bumrungrad International Hospital / Anadolu Medical Center / Fortis Memorial Research Institute / Prince Court Medical Centre - Kuala Lumpur / Bangkok Hospital Medical Center / Buddhist Tzu Chi Medical Foundation / Al Khor Hospital / The Cuban Hospital / Qatar Rehabilitation Institute / Hamad General Hospital / Communicable Disease Center / Saint Jude Medical Clinic / Tanchuling General Hospital / Casimiro General Hospital / Flora District Hospital / Notre Dame de Chartres Hospital / Isaac and Catalina Medical Center / Sto. Ara Medical Hospital / Cayetano Medical Clinic / Divine Care Hospital / Holy Family Medical Clinic / Lemery Doctors' Medical Center / N. L. Villa Memorial Medical Center / St. Joseph Healthcare Inc. / United Doctors of St. Camillus de Lellis Hospital / Dr. Ahmad El Masri Hospital / American University of Beirut Medical Center / Bikhazi Medical Group / Mount-Lebanon Hospital, Gharios Medical Center / Hôpital Libano Français / Cedars Jebel Ali International Hospital / Chittagong Maa-O-Shishu Hospital / Dhaka Medical College & Hospital / Eastern Hospital & Medical Research Centre / Rashid Hospital

Companies and Industries

USA

Stryker / Regeneron Pharmaceuticals / Quest Diagnostics / Pfizer / Nashville, Tenn.-based HCA Healthcare / Merck / Magellan Health / Louisville, Ky.-based Kindred Healthcare / Long Beach, Calif.-based Molina Healthcare / Laboratory Corp / King of Prussia, Penn.-based Universal Health Services / Johnson & Johnson / IQVIA / Gilead Sciences / Franklin, Tenn.-based Community Health Systems / Envision Healthcare / Eli Lilly / DaVita / Danaher / Dallas-based Tenet Healthcare / CVS Health / Cigna / Zimmer Biomet / WellCare Health Plans / UnitedHealth Group / Centene / Celgene / Bristol-Myers Squibb / Brentwood, Tenn.-based LifePoint Health / Boston Scientific / Biogen / Becton Dickson / Baxter International / AbbVie / Abbott Laboratories / Siemens Healthineers / Chembio Diagnostics Inc / Alere / Quest Diagnostics, Inc / Cardinal Health / Thermo Fisher Scientific Inc / Vertex Pharmaceuticals / Mylan Pharmaceuticals / Perrigo Pharmaceuticals / Acella Pharmaceuticals / Athens Research and Technology / Facet Medical Technologies / WuXi Apptec / Sebela Pharmaceuticals / Osmotica Pharmaceutical / Antios Therapeutics / Biothera Pharmaceuticals / MD Biosciences / MGC Diagnostics / ProMed Prototypes / Vida Diagnostics

Europe

Siemens Healthineers / Hoffmann-La Roche Ltd / Trinity Biotech / BioMérieux SA / OJ-Bio Ltd. / Amicomed Inc. / HealthBeacon / Healthera Ltd / Liva Healthcare / Oviva AG / Oxitone Medical / Pacifica Labs Inc. / Px HealthCare / Qured / Novigenix / Genomcore - Made of Genes / Lunaphore Technologies / Gondola Medical Technologies / InfiniteVision Optics / Newsenselab / Accord / Novo Nordisk / Boehringer Ingelheim / AstraZeneca / Teva Pharmaceutical Industries / GlaxoSmithKline / Sanofi / Novartis / Roche / Bayer / ThioMatrix / ABF Pharmaceutical Services / Aperion Biologics / Ares Genetics / BlueSky Vaccines / Haplogen / Hookipa Pharma / s-TARget Therapeutics / Themis Bioscience / Pfizer / Epitopoietic Research Corporation (ERC) / Integra LifeSciences / FLUIDDA / Mithra Pharmaceuticals / A-Mansia Biotech / Taconic Biosciences / BioPorto Diagnostics / Expres2ion Biotechnologies / Veloxis Pharmaceuticals / Bavarian Nordic / Zyla Life Sciences / Medix Biochemica / TILT Biotherapeutics / Charles River Laboratories / Finvector Vision Therapies / Carlina Technologies

Asia/Middle East

Trivitron Healthcare / Bio-Rad Labs Inc. / Mabworks Biotech / Charles River Laboratories / Crown Bioscience / CStone Pharmaceuticals / Hologic / Origene / Sino Biological / Shenogen Pharma / Paragon Medical / Clover Biopharmaceuticals / HitGen / Yao Pharma / Magpie Pharmaceuticals / BioMarin Pharmaceutical / Charles River Laboratories / Navitas Life Sciences / Richcore Lifesciences / Zumutor Biologics / Vyome Therapeutics / Sphaera Pharma / Bharat Biotech / Global Pharma Tek / Hinge Clinica / Sun Pharmaceuticals / Kringle Pharma / Ora Clinical / Noile-Immune Biotech / Teleflex Medical / LegoChemBio / Bridge Biotherapeutics / Samsung Bioepis / HanAll Biopharma / Eutilex / Daewoong Pharmaceutical / STC-Stem Cell Treatment & Research Institute (STRI) / GC Pharma / Novotech / Neopeutics / Invitrogen / Chugai Pharmabody Research / GlaxoSmithKline / Singapore Advanced Biologics / Sphaera Pharma / Genome & Company / Immunwork / Worldwide Clinical trials

Societies and Associations

USA

Infectious Diseases Society / Infectious Disease Association of California / Society for Healthcare Epidemiology of America / National Foundation for Infectious Diseases / Association of Medical Microbiology and Infectious Disease Canada (AMMI) / Canadian Nurses Association (CNA) / Infectious Diseases Society of America (IDSA) / Provincial Infectious Diseases Advisory Committee (PIDAC) / Society for Healthcare Epidemiology of America / International Society for Infectious Diseases (ISID) / Immunize Canada / Ontario Hospital Association (OHA) / American Academy of Allergy Asthma & Immunology / American Board of Allergy & Immunology / National Institute of Allergy and Infectious Diseases / College of American Pathologists / Centers for Disease Control / American Academy of Ambulatory Care Nursing (AAACN) / Case Management Society of America (CMSA) / Association for Professionals in Infection Control and Epidemiology (APIC) / National Association for Healthcare Quality (NAHQ) / Society For Health Care Strategy & Market Development (SHSMD) / American Society for Microbiology

Europe

European Society for Paediatric Infectious Diseases: ESPID / European Society of Clinical Microbiology and Infectious Diseases / European Respiratory Society / Healthcare Infection Society / European Lung Foundation – ELF / European Association of Urology / The European Academy of Allergy and Clinical Immunology / ESICM – European society of intensive medicine / British Society for Antimicrobial Chemotherapy / Society for Hematopathology / European AIDS Clinical Society / European Centre for Disease Prevention and Control / International Society for Infectious Diseases / British Society for Antimicrobial Chemotherapy (BSAC) / Microbiology Society / British Association for Sexual Health and HIV (BASHH) / The Hospital Infection Society (HIS) / Infection Prevention Society (IPS) / British Society for Medical Mycology (BSMM) / The Royal Society of Tropical Medicine and Hygiene (RSTMH) / UK Clinical Virology Network / Royal Society for Public Health (RSPH) / Health Protection Scotland

Asia/Middle East

Asia Pacific Society of Infection Control – APSIC / Asian Society for Pediatric Infectious Diseases: ASPID / The Urological Association of Asia / Infection Control Association / ASID - Australasian Society for Infectious Diseases / Japan Society for Surgical Infection / Asia-Pacific Society of Clinical Microbiology and Infection (APSCMI) / Association for Professionals in Infection Control and Epidemiology / Israeli Society for Infectious Diseases / The South East Asia Infectious Disease Clinical Research Network (SEAICRN) / The Asia Fungal Working Group (AFWG) / The Asian Association of UTI & STI (AAUS) / Infectious Disease Association of Thailand / The Hong Kong Infection Control Nurses’ Association / Emirates Society of Emergency Medicine (ESEM) / Infection Control Association (Singapore) / Society of Infectious Disease (Singapore) / The Lebanese Society of Infectious Diseases and Clinical Microbiology

Max Seats
15 seats
Speaker Time
20 mins
Workshop Proposal
Click Here

Conference

Our Experts

General Info

get in touch

+1-778-766-2134

quick links

4th World Forum on Infectious Diseases and Antimicrobial Resistance

Why Should You Attend IDAMR 2026?

PRESENTATION

CONNECT

EXCEL

PUBLICATION

COLLABORATION AND FRIENDSHIP

REINVENT SKILLS IN PROFESSIONAL DEVELOPMENT WORKSHOPS

LEARN ABOUT THE LATEST DEVELOPMENTS

CAPITALIZE ON YOUR TIME BY VISITING THE EXHIBITS

GET EXCEPTIONAL VALUE FOR YOUR REGISTRATION FEE

TRAVELING

Event summary

IDAMR 2026 conference

Welcome Message

SPEAKER LINE-UP

Asghar Abbasi

Thomas Bldicke

Angelos Halaris

Alicia Beatriz Penissi

Scientific Sessions

Conference Highlights

Infectious Diseases and Global Health

15 seats

20 mins

Viral Infections

15 seats

20 mins

Bacterial Infections

15 seats

20 mins

Fungal Infections

15 seats

20 mins

Vector-borne Diseases

15 seats

20 mins

Virology and HIVAIDS

15 seats

20 mins

Immunology and Clinical Microbiology

15 seats

20 mins

Neurological and CNS Infections

15 seats

20 mins

Healthcare-Associated Infections

15 seats

20 mins

Ophthalmological Infectious Diseases

15 seats

20 mins

Lower Respiratory and Pediatric IDs

15 seats

20 mins

Genomics and Infectious disease

15 seats

20 mins

Special Session on COVID-19

15 seats

20 mins

Vaccines and Immunizations

15 seats

20 mins

Tropical Diseases and Parasitic Diseases

15 seats

20 mins

Sexually Transmitted Diseases and STIs

15 seats

20 mins

Pathophysiology and Diagnosis

15 seats

20 mins

Clinical Trials and Case Studies

2 100+
Distinguished Speakers

3 15+
Keynote Speakers